 |
|
| Blog results | Results 1 - 10 of about 365 for lapatinib capecitabine. (0.19 seconds) |
| Sorted by relevance Sort by date |
| 1 Dec 2009 by godsmorally The cost-effectiveness of lapatinib plus capecitabine was supported by a resemblance to trastuzumab-containing regimens, and capecitabine singular, representing the established treatment regimens in NHS clinical technique. ... godsmorally - http://godsmorally.chrisbrownconnection.com/ |
| 20 Oct 2009 by Dr. NICK BACKGROUND: The Lapatinib Expanded Access Program (LEAP) was designed to provide access to lapatinib plus capecitabine for HER2-positive metastatic breast cancer patients who previously received an anthracycline, a taxane, ... CANCER AND IMPORTANT MEDICAL NEWS - http://cancerology.blogspot.com/ |
| 25 Aug 2009 status: recruiting, condition summary: breast cancer; metastatic cancer. Clinical Trials Updates During the Last 7 Days - http://clinicaltrialsfeeds.org/clinical-trials/r... [ More results from Clinical Trials Updates During the Last 7 Days ] |
| 12 Aug 2009 by Christopher M. Hughes, MD Using the investigator assessment of the clinical benefit response rate a greater proportion of subjects in the lapatinib+capecitabine group (37%) than in the capecitabine group (21%) achieved clinical benefit (two-sided p-value: 0.001) ... The Health Care Reform Debate Blog - cmhmd - http://cmhmd.blogspot.com/ |
| 23 Jun 2009 by admin In its final appraisal determination NICE acknowledges that lapatinib is a clinically effective option, noting that lapatinib plus capecitabine demonstrated improved time to progression (TTP) and progression free survival (PFS) ... Nordwave Great Britain - http://nordwave.net/Great_Britain/ |
| 4 Apr 2007 by Sonpavde, G., Geyer, CE, Forster, J., Cameron, D. Correspondence from The New England Journal of Medicine -- Lapatinib plus Capecitabine in Breast Cancer. NEJM - Articles - http://content.nejm.org/ [ More results from NEJM - Articles ] |
| 8 Sep 2009 by BJS The FDA approved this drug in March of 2007 for patients with breast cancer who were already using the chemotherapeutic agent capecitabine. Lapatinib works by inhibiting the tyrosine kinase activity associated with the two oncogenes ... Science Blog - Science news straight from... - http://www.scienceblog.com/cms/frontpage1 - References |
| 30 Oct 2009 NICE has rejected oral Tyverb (lapatinib) alongside capecitabine and it published the decision in its Appraisal Consultation Document (ACD). It is due to give final guidance on the issue later this year. ... Nursing in Practice - http://www.nursinginpractice.com/rss.asp |
| 6 Aug 2009 by plasmanegative lin, nu, lapatinib and capecitabine for the treatment of brain metastases in patients with her2+ breast cancer — an updated analysis from egf105084., presented at the 2007 san antonio breast cancer symposium, san antonio, tx, ... Plasma negative - http://hardwarereactor.de/plasmanegative/ |
| 17 Dec 2007 Study Shows TYKERB Combination Reduced the Size of Brain Tumors Associated with HER2-Positive Breast Cancer GlaxoSmithKline announced today results from the ext. Drugs.com - Clinical Trials - http://www.drugs.com/clinical_trials.html [ More results from Drugs.com - Clinical Trials ] |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
